Travere Therapeutics (TVTX) Asset Writedowns and Impairment (2014 - 2022)

Travere Therapeutics' Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at -$1.0 million for Q4 2022.

• Quarterly Asset Writedowns and Impairment fell 17.96% year-over-year to -$1.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.0 million (up 108.63% YoY) and the FY2025 annual result came in at $684000.0, down 75.74% from the prior year.
• Asset Writedowns and Impairment was -$1.0 million for Q4 2022 at Travere Therapeutics, down from $329000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $25.5 million in Q1 2019 and bottomed at -$1.0 million in Q4 2022.
• A 4-year average of $2.9 million and a median of $481000.0 in 2021 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment sank 139.28% — and 2022, when it jumped 94.87%.
• Travere Therapeutics' Asset Writedowns and Impairment stood at $25.5 million in 2019, then tumbled by 91.27% to $2.2 million in 2020, then sank by 139.28% to -$874000.0 in 2021, then decreased by 17.96% to -$1.0 million in 2022.
• Business Quant data shows TVTX's Asset Writedowns and Impairment at -$1.0 million in Q4 2022, $329000.0 in Q3 2022, and $792000.0 in Q2 2022.